TY - JOUR
T1 - Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes
AU - Hazen, Sanne Marije J.A.
AU - Sluckin, Tania C.
AU - Intven, Martijn P.W.
AU - Beets, Geerard L.
AU - Beets-Tan, Regina G.H.
AU - Borstlap, Wernard A.A.
AU - Buffart, Tineke E.
AU - Buijsen, Jeroen
AU - Burger, Jacobus W.A.
AU - Van Dieren, Susan
AU - Furnée, Edgar J.B.
AU - Geijsen, E. Debby
AU - Hompes, Roel
AU - Horsthuis, Karin
AU - Leijtens, Jeroen W.A.
AU - Maas, Monique
AU - Melenhorst, Jarno
AU - Nederend, Joost
AU - Peeters, Koen C.M.J.
AU - Rozema, Tom
AU - Tuynman, Jurriaan B.
AU - Verhoef, Cornelis
AU - De Vries, Marianne
AU - Van Westreenen, Henderik L.
AU - De Wilt, Johannes H.W.
AU - Zimmerman, David D.E.
AU - Marijnen, Corrie A.M.
AU - Tanis, Pieter J.
AU - Kusters, Miranda
N1 - Publisher Copyright:
© 2024 American Medical Association. All rights reserved.
PY - 2024/2/15
Y1 - 2024/2/15
N2 - Importance: Neoadjuvant short-course radiotherapy was routinely applied for nonlocally advanced rectal cancer (cT1-3N0-1M0 with >1 mm distance to the mesorectal fascia) in the Netherlands following the Dutch total mesorectal excision trial. This policy has shifted toward selective application after guideline revision in 2014. Objective: To determine the association of decreased use of neoadjuvant radiotherapy with cancer-related outcomes and overall survival at a national level. Design, Setting, and Participants: This multicenter, population-based, nationwide cross-sectional cohort study analyzed Dutch patients with rectal cancer who were treated in 2011 with a 4-year follow-up. A similar study was performed in 2021, analyzing all patients that were surgically treated in 2016. From these cohorts, all patients with cT1-3N0-1M0 rectal cancer and radiologically unthreatened mesorectal fascia were included in the current study. The data of the 2011 cohort were collected between May and October 2015, and the data of the 2016 cohort were collected between October 2020 and November 2021. The data were analyzed between May and October 2022. Main Outcomes and Measures: The main outcomes were 4-year local recurrence and overall survival rates. Results: Among the 2011 and 2016 cohorts, 1199 (mean [SD] age, 68 [11] years; 430 women [36%]) of 2095 patients (57.2%) and 1576 (mean [SD] age, 68 [10] years; 547 women [35%]) of 3057 patients (51.6%) had cT1-3N0-1M0 rectal cancer and were included, with proportions of neoadjuvant radiotherapy of 87% (2011) and 37% (2016). Four-year local recurrence rates were 5.8% and 5.5%, respectively (P =.99). Compared with the 2011 cohort, 4-year overall survival was significantly higher in the 2016 cohort (79.6% vs 86.4%; P <.001), with lower non-cancer-related mortality (13.8% vs 6.3%; P <.001). Conclusions and Relevance: The results of this cross-sectional study suggest that an absolute 50% reduction in radiotherapy use for nonlocally advanced rectal cancer did not compromise cancer-related outcomes at a national level. Optimizing clinical staging and surgery following the Dutch total mesorectal excision trial has potentially enabled safe deintensification of treatment.
AB - Importance: Neoadjuvant short-course radiotherapy was routinely applied for nonlocally advanced rectal cancer (cT1-3N0-1M0 with >1 mm distance to the mesorectal fascia) in the Netherlands following the Dutch total mesorectal excision trial. This policy has shifted toward selective application after guideline revision in 2014. Objective: To determine the association of decreased use of neoadjuvant radiotherapy with cancer-related outcomes and overall survival at a national level. Design, Setting, and Participants: This multicenter, population-based, nationwide cross-sectional cohort study analyzed Dutch patients with rectal cancer who were treated in 2011 with a 4-year follow-up. A similar study was performed in 2021, analyzing all patients that were surgically treated in 2016. From these cohorts, all patients with cT1-3N0-1M0 rectal cancer and radiologically unthreatened mesorectal fascia were included in the current study. The data of the 2011 cohort were collected between May and October 2015, and the data of the 2016 cohort were collected between October 2020 and November 2021. The data were analyzed between May and October 2022. Main Outcomes and Measures: The main outcomes were 4-year local recurrence and overall survival rates. Results: Among the 2011 and 2016 cohorts, 1199 (mean [SD] age, 68 [11] years; 430 women [36%]) of 2095 patients (57.2%) and 1576 (mean [SD] age, 68 [10] years; 547 women [35%]) of 3057 patients (51.6%) had cT1-3N0-1M0 rectal cancer and were included, with proportions of neoadjuvant radiotherapy of 87% (2011) and 37% (2016). Four-year local recurrence rates were 5.8% and 5.5%, respectively (P =.99). Compared with the 2011 cohort, 4-year overall survival was significantly higher in the 2016 cohort (79.6% vs 86.4%; P <.001), with lower non-cancer-related mortality (13.8% vs 6.3%; P <.001). Conclusions and Relevance: The results of this cross-sectional study suggest that an absolute 50% reduction in radiotherapy use for nonlocally advanced rectal cancer did not compromise cancer-related outcomes at a national level. Optimizing clinical staging and surgery following the Dutch total mesorectal excision trial has potentially enabled safe deintensification of treatment.
U2 - 10.1001/jamaoncol.2023.5444
DO - 10.1001/jamaoncol.2023.5444
M3 - Article
SN - 2374-2437
VL - 10
SP - 202
EP - 211
JO - JAMA Oncology
JF - JAMA Oncology
IS - 2
ER -